Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18569190 | 1.00 | TGFBR1 (0.42) | TGFBR1MMECA12CA1CA2 | |
| SCHEMBL31688106 | 0.86 | QRFPR (0.41) | TGFBR1MMECA12CA1CA2 | |
| SCHEMBL9952740 | 0.84 | TGFBR1 (0.43) | TGFBR1MMECA12CA1CA2 | |
| SCHEMBL783082 | 0.82 | TGFBR1 (0.57) | TGFBR1MMECA1CA2 | |
| SCHEMBL783083 | 0.82 | TGFBR1 (0.57) | TGFBR1MMECA1CA2 | |
| SCHEMBL29556650 | 0.82 | TGFBR1 (0.57) | TGFBR1MMECA1CA2 | |
| SCHEMBL24072884 | 0.80 | CYP2C9 (0.43) | TGFBR1MMECA12CA1CA2 | |
| SCHEMBL12779591 | 0.80 | CYP2C9 (0.43) | TGFBR1MMECA12CA1CA2 | |
| SCHEMBL15185954 | 0.80 | TGFBR1 (0.41) | TGFBR1MMECA12CA1CA2 | |
| SCHEMBL12228626 | 0.80 | KDM4E (0.38) | CA12CA1CA9CTSCECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296958-A1 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-09-25 | — | — | US | disclosed |
| EP-4531885-A1 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | The Administrators of The Tulane Educational Fund (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023235319-A1 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023235232-A2 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-4153319-A1 | METHOD FOR OBTAINING AN EXTRACT OF SANDALWOOD, COMPOSITIONS COMPRISING SAME AND COSMETIC USES THEREOF | ISP Investments LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-02-02 | — | — | US | disclosed |
| US-20050164515-A9 | Biological control of nanoparticle nucleation, shape and crystal phase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-07-28 | — | — | US | disclosed |
| EP-0789710-A1 | PEPTIDES FOR ANTI-ALLERGY TREATMENT | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014333-A1 | PEPTIDES FOR ANTI-ALLERGY TREATMENT | PEPTIDE THERAPEUTICS LIMITED (GB) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296958-A1 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | OPRD1, OGFR, OPRL1 | TGFBR1 2797/4885MME 757/4885CA12 1806/4885 |
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | PLK1, POLR1E, POLK | TGFBR1 3489/4885MME 1643/4885CA12 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.